Background: Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) have been associated with a high remission rate of type 2 diabetes mellitus (T2DM). However, whether such remission is associated with full restoration of postprandial glucose profile and/or the potentially nonrestored glycemic profile is associated with altered beta cell function, and relapse of T2DM over time is unknown. Methods: Cross-sectional studies comparing (1) glucose and proinsulin/insulin response to a standardized liquid mixed meal (SLMM) challenge (n = 31), (2) glucose response in normal living conditions assessed using continuous glucose monitoring (CGM) (n = 16), and prospective observational study comparing (3) rates of relapse of T2DM after surgery (n = 232) in subjects with remission of T2DM ensuing RYGBP or SG. Results: In RYGB individuals, SLMM elicited faster and sharper rise in plasma glucose compared with SG, with 88.2% and 42.9% of the study subjects presenting respectively a peak glucose more than 180 mg/dL (all, P < 0.05). During CGM, average percent time in hyperglycemic and hypoglycemic range was larger in RYGBP (respectively, 4.6% and 12.7%) compared with SG subjects (respectively, 0.4% and 3.2%; both P < 0.05). However, (1) no differences were found in fasting or stimulated proinsulin/insulin ratio, and (2) higher rates of T2DM relapse were observed after SG (hazard ratio: 2.339; P = 0.034). Conclusions: Remission of T2DM after RYGBP and SG is associated with distinct glycemic profiles. However, longer time spent in hyperglycemia and in hypoglycemia after RYGBP compared with SG is not associated with persistence of altered beta cell function or higher rates of relapse of T2DM over time.
States, 4 relapse of diabetes (14%-43%) [5] [6] [7] as well as postprandrial hypoglycemia after this surgical technique has been reported in a significant proportion of subjects suggesting glucose homeostasis is not fully restored after this type of surgery. 5, 6, 8, 9 It has been shown that a standardized mixed meal challenge results in an early and exaggerated glucose peak after RYGBP compared with after adjustable gastric banding (AGB) in subjects with normal glucose tolerance before surgery. 10 Importantly, the reported glucose peak after RYGBP in subjects with unaltered glucose tolerance exceeds postprandrial plasma glucose threshold recommended by the American Diabetes Association for the metabolic control in subjects with T2DM. 11 That the hyperglycemia ensuing RYGBP could be viewed as undesirable is exemplified by 2 different observations. First, tight glycemic control in patients with newly diagnosed T2DM has been associated with favorable maintenance of beta-cell function. 12 Second, postprandrial hyperglycemia has been proposed as potential mechanism for increased beta-cell burden and progression of impaired glucose tolerance (IGT) to T2DM. 13 On the contrary, in recent years, several studies have reported on hyperinsulinemic hypoglycemia occurring after RYGBP with some cases presenting with neuroglucopenia. 8, 9 It has been proposed that accelerated gastric emptying after RYGBP because of the absence of the pylorus could account, at least in part, for the 2 earlier-mentioned findings in RYGBP patients. Accelerated gastric emptying would favor a higher rate of appearance in plasma of ingested glucose, 10 and the ensuing exaggerated insulin peak could be involved in late postprandrial hypoglycemia. 14 Sleeve gastrectomy (SG) is gaining acceptance as MS technique. 4 SG consists of a calibrated vertical gastrectomy with preservation of the pylorus. 15 Gastric emptying after SG has been reported accelerated in several 16 but not all studies. 17 Data obtained in nondiabetic obese subjects suggest SG results in a more physiological postprandial glucose profile, with later and lower glucose peak, along with lower insulin secretory response and lower rates of late hypoglycemia. 18 However, direct comparison of the postprandial glucose profile in subjects in remission of T2DM after SG or RYGBP once stable weight loss has been achieved has to our knowledge not previously been reported. Of note, we and other have reported similar rates of remission of T2DM after SG compared with RYGBP. 7, 19 Moreover, we have previously reported relapse of T2DM after MS was not predicted by the surgical technique, be it SG or RYGBP. 7 However, the relative low number of patients with relapse of T2DM in our series may have hampered the power of the study to indentify subtle differences between the 2 surgical procedures.
Against this background, we hypothesized that RYGBP compared with SG would be associated with an abnormal postprandial glucose profile in subjects with postsurgical remission of T2DM, with that being associated with an altered beta cell function, and higher rates of relapse of diabetes over time. To test our hypothesis, we compared (1) the glucose response with a standardized liquid mixed meal challenge and in normal living conditions, (2) the proinsulin/insulin
METHODS

Study 1: Glucose and Hormonal Profile in Response to a Standardized Liquid Mixed Meal Challenge
Seventeen individuals (4 men/13 women) who had undergone standardized RYGBP and 14 (3 men/11 women) individuals that had undergone standardized SG at our institution at least 24 months before evaluation participated in this cross-sectional study. All study subjects presented T2DM for at least 6 months antedating surgery and postsurgical remission of T2DM. 20 Study participants were selected among a series of 232 subjects with T2DM who had undergone MS at our institution between 2005 and 2010 (see later). Patients in the RYGBP and SG groups were matched for sex, age, presurgical glycated hemoglobin (HbA1c) and characteristics of T2DM, preand postsurgical body mass index (BMI), as well as insulin sensitivity as assessed by the homeostatic model assessment of insulin resistance [HOMA-IR = fasting glucose (nmol/L) * fasting insulin (μU/L)/22.5], and time of follow up after surgery ( Table 1) . The Hospital Ethics Committee approved the study, and written informed consent was obtained from all the participants.
Subjects attended the research facility at 8:30 AM after an overnight fast. Subjects were weighed and measured wearing light clothes, and a cannula was then inserted into distal forearm for blood sample collection. Blood was withdrawn at baseline for measurement of plasma glucose, insulin, and proinsulin in the fasting state. Subjects then consumed a 250 mL standard meal (Isosource Energy, Novartis, Basel, Switzerland) containing 398 Kcal, 50% as carbohydrates, 35% as fat, and 15% as proteins. Additional blood samples for plasma glucose and hormone assessment were collected at 30, 60, 90, and 120 minutes after meal ingestion. Samples were centrifuged immediately at +4
• C and stored at −80 • C until assayed. Plasma glucose and insulin was measured as previously described. 21 Proinsulin was measured using a RIA method (Millipore Corporation, Billerica, MA), with an antibody that is specific for proinsulin and with no cross-reactivity to insulin.
Characteristics of the glucose response to the standardized liquid mixed meal (SLMM) in our analysis included peak glucose concentration, time to peak glucose, nadir glucose, the area under the curve (AUC) of glucose throughout the 2-hour duration of the test, and in the first and second hour after meal ingestion. Beta cell function was assessed as the fasting-, and stimulated proinsulin to insulin ratio, as well as the proinsulinogenic index calculated as the increment in proinsulin from time 0 to time 30, divided by the change in plasma glucose in the same time frame.
Study 2: Continuous Glucose Monitoring
To assess whether glucose profile differed between RYGBP and SG subjects in normal living conditions, patients who had undergone the SLMM challenge study were invited to participate in the cross-sectional continuous glucose monitoring (CGM) study. Eight of 17 individuals in the RYGBP group and 8 of 14 individuals in the SG-group agreed to participate. Clinical characteristics of participants in the CGM study were not statistically different compared with those who declined participation. Furthermore, the RYGBP and SG groups were matched for the same variables as in study 1 (data not shown). The Hospital Ethics Committee approved the study, and written informed consent was obtained from all the participants.
Interstitial tissue glucose (IG) was recorded with the MiniMed continuous glucose monitoring system (Medtronic Diabetes, Northridge, CA) as previously reported. 21 Continuous glucose monitoring was performed over a 72-hour period on consecutive labor days. Patients were advised not to change their lifestyle and to keep records of any food intake during the monitoring period. At completion, data were downloaded and average IG, minimum IG, maximum IG, standard deviation of IG distribution, and time in hyperglycemia and in hypoglycemia as percent of the monitored time were calculated. Hypoglycemia was defined as IG value lower than 70 mg/dL and 2 different cutoff values were used for hyperglycemia more than 160 mg/dL and more than 180 mg/dL.
11,22
Study 3: Relapse of T2DM After RYGBP or SG A total of 232 subjects were included in this prospective nonrandomized observational study. Inclusion criteria for the study consisted of a diagnosis of T2DM at least 6 months before surgery, and a follow-up of at least 24 months at the time of current analysis. Selection of SG as MS technique was based on the presence of a large body mass index, estimated operative risk, or the presence of an enlarged liver. 7 Data of study patients were prospectively collected before surgery and at 4, 8, 12, 18, 24, 30, 36 months and yearly thereafter in the postsurgical period. Data collection included demographics (age, sex, time since diagnosis of T2DM, and type of antidiabetic medication), anthropometrics (weight, height, systolic, and diastolic blood pressure), and biochemical measurements (fasting plasma glucose, and HbA1c). Diabetes remission was defined as fasting plasma glucose less than 126 mg/dL along with HbA1c less than 6.5% in the absence of hypoglycemia medication and lasting for at least 12 months. 20 Diabetes relapse was annotated when a particular subject fulfilled biochemical criteria for T2DM 11 and/or was treated with hypoglycemic medication after a period of remission as defined earlier. 7 Postoperative weight loss was expressed as a percentage of presurgical excess weight loss (%EWL), 7 and weight regain was expressed as weight gained from nadir to the last evaluation as percentage of nadir weight.
Statistical Analysis
Statistical analysis was performed using SPSS 17.0. Normality of study variables was assessed by Kolmogorov-Smirnov normality test. Continuous variables with normal distribution are expressed as mean ± standard deviation. Continuous variables with non-normal distribution are reported as median and interquartile range. The AUC of glucose and insulin during SLMM were calculated using the trapezoidal method. Differences between groups were evaluated by parametric (t-test for quantitative variables and χ 2 test for categorical variables) or nonparametric tests (Mann-Whitney test for quantitative variables and Fisher exact test for categorical variables) as appropriate. Multivariable Cox regression analysis was used to evaluate independent effect of type of surgery on T2DM remission and relapse. Multivariable analysis included all variables with known or suspected biological effect on T2D outcomes 7, 23 and variables that showed statistically significant differences between groups in univariate analysis. Statistical significance was set at P < 0.05.
RESULTS
SLMM Test
Clinical features of the participants in the SLMM study are shown in Table 1 . Mean follow up after surgery was 3.3 ± 1.3 years. At the time of evaluation, average BMI was in the obesity range (31.4 ± 4.0 kg/m 2 ). As per selection criteria, fasting plasma glucose (91.6 ± 8.9 mg/dL) and HbA1c (5.3 ± 0.4%) were in the normal range in all study participants with no significant differences between groups.
The time course of plasma glucose and insulin responses to the SLMM challenge is shown in Figure 1 . In RYGB individuals, meal Copyright © 2014 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. ingestion elicited a rapid and sharp rise in plasma glucose, with mean glucose peak of more than 200 mg/dL (222 ± 34 mg/dL), and time to peak glucose of 33.5 ± 9.9 minutes. Peak glucose was followed by a pronounced decline (121.0 ± 29.2 mg/dL in the 60 minutes after peak glucose), reaching a 2-hour plasma glucose lower than that at baseline (fasting: 91.8 ± 9.7 mg/dL, 2 hours: 83.7 ± 18.3, P = 0.024). Fifteen (88.2%) and 16 (94.1%) of the 17 RYGBP subjects presented a peak glucose of more than 180 mg/dL and more than 160 mg/dL, respectively. Plasma glucose of less than 60 mg/dL at 2 hours after SLMM intake was encountered in 1 subject (5.9%) in the RYGBP group. In the SG group, meal ingestion was associated with lower (161.7 ± 8.6 mg/dL, P < 0.001) and longer time to glucose peak (47.1 ± 19.4 minutes, P = 0.028), less pronounced glucose decline (64.0 ± 34.3 mg/dL, P < 0.001), and significantly higher 2-hour plasma glucose (100.4 ± 20.9 mg/dL, P = 0.024). Six (42.9%) and 7 patients (50%) of the 14 SG subjects presented with peak glucose of more than 180 mg/dL and of more than 160 mg/dL, respectively. No one in the SG group presented a 2-hour plasma glucose of less than 60 mg/dL. Thus, the proportion of subjects with postprandrial glucose above the proposed thresholds was larger in the RYGBP than in the SG group (both P < 0.05). As shown in Table 1 , the different glucose pattern after meal ingestion did not translate into statistically significant differences in AUC 0-120 glucose between the 2 surgical groups. Of note, separate comparison of the AUC glucose in the first 60 minutes and over the second hour between the RYGBP and SG groups showed a larger early (P < 0.001) but not late glucose response (P = 0.625) to meal intake associated with RYGBP. Paralleling the observed glucose pattern, subjects in the RYGBP group showed a sharp increase in plasma insulin, with higher peak insulin compared with the SG group (RYGBP: 208.4 ± 119.2 mU/L, SG: 125.1 ± 58.8, mU/L; P = 0.019) followed by lower plasma insulin levels at 120 minutes (RYGBP: 17.4 ± 10.1 mU/L, SG: 32.4 ± 15.7 mU/L, P = 0.004) after SLMM intake. The earlier higher glucose values in the hour after meal ingestion in the RYGBP group occurred despite larger AUC 0-60 for insulin (Table 1 , P = 0.014) and in the absence of significant difference in insulinogenic index (Table 1 , P = 0.430) or HOMA-IR (Table 1 , P = 0.902) compared with the SG group. Nonetheless, the exaggerated insulin response in RYGBP subjects was not associated with higher proinsulin to insulin (PI/I) ratio at baseline or at 30 minutes after meal intake (Table 1 : P = 0.867 and P = 0.214, respectively), nor a large proinsulinogenic index (Table 1 , P = 0.168) or a larger increment in the PI/I ratio of over the first 30 minutes after meal ingestion (Table 1 , P = 0.370)
Continuous Glucose Monitoring
Clinical characteristics of participants in this study and the main findings in the CGM study are shown in Table 2 . The 2 study groups were comparable for sex, DM duration before surgery, time elapsed after surgery to the time of evaluation, and BMI and HbA1c distributions at evaluation. Average IG throughout the 72-hour observation period was similar between surgical groups (P = 0.816). However, RYGBP subjects presented higher maximum (P < 0.001) and lower minimum (P = 0.045) IG. As consequence, higher glycemic variability estimated as the standard deviation of the distribution of glucose values over the 72-hour observation period was larger in the RYGBP group than in the SG group (P = 0.003). Furthermore, RYGBP individuals spend more time in hyperglycemia (P = 0.009), more time in hypoglycemia (P = 0.019), and correspondingly less time in euglycemia (P = 0.007) than the SG individuals. Finally, 6 (75%), 8 (100.0%), and 5 (71.4%) of 8 subjects in the RYGBP presented IG readings of more than 180, more than 160, and less than 60 mg/dL, respectively, throughout the 72-hour observation period compared with 0 (0%, P = 0.002), 3 (35.7%, P = 0.007), and 2 (25%, P = 0.131) in the SG group. ± 9.6 years; P = 0.002), presented lower BMI (RYGBP: 44.5 ± 4.9, SG: 47.5 ± 7.1 Kg/m 2 ; P < 0.001), were treated less frequently with insulin (RYGBP: 21.5%, SG: 36.9%; P = 0.009), and presented better glycemic control (RYGBP-HbA1c: 7.3% ± 1.8% and fasting plasma glucose (FPG): 166.2 ± 63.0 mg/dL versus SG-HbA1c: 7.8% ± 1.8% and FPG: 183.8 ± 63.8 mg/dl; respectively, P = 0.045 and P = 0.036). Mean follow-up for the whole cohort was 48.7 ± 21.7 months, with that being longer in the RYGBP group (RYGBP: 55.5 ± 22.6, SG: 41.5 ± 18.2 months, P < 0.001). In our cohort, RYGBP was associated with larger %EWL than SG throughout the first 24 months after surgery, and larger %EWL at nadir (RYGBP: 76.4 ± 19.3, SG: 70.2 ± 19.8, P = 0.017) (Fig. 2) . No statistically significant differences in %EWL were found between the 2 groups thereafter. Similarly, no difference in weight regain was observed between surgical groups (RYGBP: 16.5% (0.0%-28.8%), SG: 10.5% (0.0%-25.0%), P = 0.298).
Remission 
DISCUSSION
Our data show that yet RYGBP and SG are associated with T2DM remission in a large and comparable proportion of subjects, the glucose profile associated with the improved metabolic state is distinct after the 2 types of surgeries. Despite fasting plasma glucose and HbA1c being below the diagnostic thresholds, RYGBP patients present glucose excursions in the hyperglycemic and hypoglycemic range both in experimental and normal living conditions. However, the enlarged glucose variability in RYGBP patients does not seem to be associated with altered beta-cell function or increased likelihood of relapse of T2DM.
Our study expands to subjects in remission of T2DM on earlier observations of an altered glycemic profile after an SLMM challenge after RYGBP. A prompt and exaggerated peak glucose has been reported at long-term after RYGBP compared with AGB in nondiabetic subjects. 10, 21 Likewise, in our study, an earlier and exaggerated peak of glucose was observed in RYGBP compared with SG-operated individuals after an SLMM challenge. Admittedly, it could be argued that our sampling schedule precluded finding potential differences in peak glucose occurring before the 30-minute time point. 24 Nonetheless, our CGM data would further support the contention that subjects in remission of T2DM after either RYGBP or SG present distinct glycemic profiles. In our series of subjects, peak glucose, time spent in hyperglycemia, and the proportion of subjects presenting with IG readings of more than 160 or more than 180 mg/dL was higher in RYGBP subjects when assessed under normal living conditions by means of CGM. IG in normal living conditions in subjects who had undergone RYGBP has seldom been reported and has mainly been evaluated in the context of referrals either because of hypoglycemic or because of dumping symptoms. 21, 25, 26 Hanaire et al 25 reported on the comparison of the IG profiles in RYGBP subjects, nonoperated diabetic subjects, and healthy controls. Postprandial peak glucose was comparable in the RYGBP and diabetic groups, although nonoperated individuals presented with hyperglycemia (>160 mg/dL) for a larger percent time of the observation period (35.3% ± 25.6%) compared with the RYGBP group (9.0% ± 9.2%). Interestingly, postprandial hyperglycemia in that study was more commonly observed in subjects with presurgical history of T2DM compared with those without diabetes at baseline. To our knowledge, CGM has not previously been reported after SG. CGM data in our SG series showed lower peak glucose and less percent time spent in hyperglycemia compared with RYGBP, with observed values being similar to those reported by Hanaire et al 25 in healthy controls (peak glucose 155 ± 30 mg/dL, time spent in hypoglycemia 0.0% ± 0.6%). Evaluation of the mechanisms accounting for the differences in the glucose profile after RYGBP or SG is beyond the scope of our study. However, tracer studies have shown faster exogenous glucose absorption into the systemic circulation after RYGBP compared with AGB, 27 most likely reflecting gastric emptying is accelerated after RYGBP. 28, 29 Admittedly, SG has also been associated with accelerated gastric emptying of liquid and semisolid meals. 17 It is tempting to speculate that preservation of the pylorus as in SG-operated subjects would account for the less pronounced postprandrial glycemic peak after this surgical technique compared with RYGBP. However, it should be acknowledged that direct comparison of gastric emptying after SG or RYGBP has not been reported nor was assessed in our study.
Roslin et al 24 have recently reported on the occurrence of reactive hypoglycemia after an oral glucose load in 35 out 63 (56%) unselected subjects who underwent RYGBP. This is in contrast with rates of hypoglycemia observed in our series. Differences in the definition of hypoglycemia and nutrient stimuli may partly account for the seemingly discrepant results. Notwithstanding, we would like to emphasize profound differences in time spent in hypoglycemia in our 2 surgical cohorts. On average, subjects in the RYGBP in our series spent 10% of the CGM observation period in the hypoglycemic range without reporting hypoglycemic symptoms. Differences in time spent in hypoglycemia between patients in the RYGBP group in our study and those previously reported may be accounted for differences in the definition of hypoglycemia. 25, 26 Data discussed earlier would suggest that despite rates of T2DM remission being similar after RYGBP and SG, perturbations of glycemic homeostasis are still present after the former surgical technique. To get further insight into the potential implication of such distinct glycemic profiles on pancreatic beta cell function, we compared fasting and acutely stimulated proinsulin/immunoreactive insulin (PI/IRI). Fasting PI/IRI ratio provides an estimate of the efficiency of proinsulin processing by the beta cell, and this ratio is increased in subjects with T2DM. 30 Likewise, although the ratio is lower because of differences in clearance of the peptides, the disproportionate increase in the PI/IRI ratio in T2DM is maintained after acute stimulation of release. 31 Of note, neither fasting nor stimulated PI/IRI ratio differed between our surgical groups. Thus, at variance to what has been reported in subjects with T2DM, 31 our data suggest differences in glycemic variability in subjects in remission of T2DM after RYGBP or SG are not associated with dissimilar beta cell secretory quality.
Postprandial hyperglycemia is a well-established risk factor for future development of T2DM. Consequently, in this study we aimed to test this contention in the context of MS by comparing the rate of relapse of T2DM in our cohort of RYGBP-and SG-operated subjects. Of note, Chikunguwo et al 5 and DiGiorgi et al 6 have previously reported a 26% and 43% relapse rate of T2DM after RYGBP at a mean follow-up of 5 and 9 years, respectively. Similarly, Himpens et al 32 have reported a high incidence (27.9%) of IGT up to 9 years after RYGBP in subjects without T2DM antedating surgery. In contrast to what we had hypothesized, the rate of relapse of T2DM in our cohort was higher after SG than after RYGBP. SG subjects in our observational study more commonly presented with characteristics that have typically been associated with high rates of relapse of T2DM after MS. 7 We acknowledge that definite conclusion on the comparison of rates of relapse of T2DM after SG and RYGBP could only be derived from a randomized clinical trial. Statistical analysis in our observational study may not have fully accounted for differences between surgical groups at baseline. Unfortunately, the relevance of postprandial peak glucose could not be evaluated in our regression models as it was not assessed in our observational cohort. However, our data provide circumstantial evidence that higher peak glucose after RYGBP than after SG is not associated with higher rates of relapse of T2DM. The seemingly counterintuitive results observed in our cohort compared with those related to the progression of IGT to overt T2DM in nonoperated individuals could be partly explained by the nature of the postprandial peak of glucose after RYGBP. Impaired beta cell function has been shown to significantly contribute Copyright © 2014 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
to worsening glucose tolerance in first-degree relatives of subjects with T2DM. 33 In contrast, glucose absorption rather than impaired insulin secretion has been implicated as determinant of the early glucose peak after RYGBP. 10, 27 Of note, superior durability of improved metabolic control of T2DM along with improved beta cell function after RYGBP relative to SG has recently been shown in a randomized clinical trial. 34 Relevance of postprandial hyperglycemia and glycemic variability other than discussed earlier is a matter of debate. 35 The American Diabetes Association recommends plasma glucose to be lower than 180 mg/dL at 1 to 2 hours after the start of the meal. 11 Moreover, it is worthy of interest that in the recently updated guidelines of the International Diabetes Federation, based on studies in normal subjects, target postprandial hyperglycemia has been settled at 160 mg/dL between 1 and 2 hours after the start of the meal. 22 In epidemiological studies, elevated 1-hour plasma glucose after meal intake has been associated with an increased cardiovascular risk. 35 Pathophysiological studies have also demonstrated endothelial dysfunction and oxidative stress being associated with elevated postprandial glucose and glycemic variability. 35 Furthermore, it has recently been shown that not only hyperglycemia but also hypoglycemia increases cardiovascular disease burden. 36 However, intervention studies have for the most part failed to demonstrate clinical benefit of tight control of postprandrial glucose. 35 Whether the 2 types of surgery under scrutiny in our study are associated with differential effects on endothelial function and/or oxidative stress warrants further studies as these were not part of our protocol.
In summary, our study shows that long-term remission of T2DM after RYGBP and SG are associated with distinct glycemic profiles. However, longer time spent in hyperglycemia and in hypoglycemia after RYGBP compared with SG in subjects in diabetes remission after surgery does not seem to be associated with persistence of altered beta cell function nor higher rates of relapse of T2DM over time. The potential consequences of increased glucose variability after RYGBP compared with SG despite comparable outcomes of T2DM warrants further investigation.
